Lewter Lakeisha A, Arnold Rachel L, Narosov Nina B, Dussor Gregory, Kolber Benedict J
Department of Neuroscience, School of Behavioral and Brain Sciences, Center for Advanced Pain Studies, The University of Texas at Dallas, Dallas, TX, United States.
Front Neurol. 2025 Jul 10;16:1603758. doi: 10.3389/fneur.2025.1603758. eCollection 2025.
Migraine is a common neurological disorder with a typical onset in adolescence or early adulthood. Migraine is three times more common in women than men, but the definitive cause underlying the observed disparity is not fully understood. Calcitonin gene-related peptide (CGRP) is a neuropeptide and potent vasodilator that is now clearly linked to migraine based on the efficacy of drugs targeting its signaling. While the efficacy and safety of drugs targeting CGRP are now well established, there is a shortage of studies exploring sex differences between CGRP and CGRP-based therapy related to migraine. This review evaluates the preclinical literature focusing on the effect of CGRP and inhibition of CGRP signaling on migraine-like behavior in male and female rodents. For this review, PubMed database was searched using the following terms: "CGRP AND Migraine AND animal models." Papers were selected for review and risk of bias (RoB) assessment to evaluate the central question - What sex differences in CGRP signaling and migraine-like behavior are observed in rodents? CGRP itself induces pronociceptive effects in both male and female mice but when considering studies that directly compared male and females, there is a case for stronger overall effects in female rodents. Inhibition of CGRP signaling has a primarily antinociceptive effect in studies using only male or female rodents. We highlight that very few studies are conducted with adequate statistical power to measure sex differences within a single study and several studies pool mice across sexes. Given the known sex differences in the human condition, this pooling methodology may not be best practice for future studies involved CGRP in rodents. Overall, while there is clinical evidence suggesting therapeutics targeting CGRP could possibly have different gendered effects in humans, more preclinical studies need to be conducted to understand sex differences in CGRP or CGRP antagonism in migraine-like behavior.
偏头痛是一种常见的神经系统疾病,典型发病于青春期或成年早期。偏头痛在女性中的发病率是男性的三倍,但导致这种差异的确切原因尚未完全明确。降钙素基因相关肽(CGRP)是一种神经肽,也是一种强效血管舒张剂,基于靶向其信号传导的药物疗效,目前已明确其与偏头痛有关。虽然靶向CGRP的药物的疗效和安全性现已得到充分证实,但探索CGRP与基于CGRP的偏头痛治疗之间性别差异的研究却很匮乏。本综述评估了临床前文献,重点关注CGRP及其信号传导抑制对雄性和雌性啮齿动物偏头痛样行为的影响。为此综述,我们使用以下检索词在PubMed数据库中进行了检索:“CGRP与偏头痛与动物模型”。筛选出用于综述和偏倚风险(RoB)评估的论文,以评估核心问题——在啮齿动物中,CGRP信号传导和偏头痛样行为存在哪些性别差异?CGRP本身在雄性和雌性小鼠中均诱导伤害感受增强效应,但在直接比较雄性和雌性的研究中,雌性啮齿动物的总体效应似乎更强。在仅使用雄性或雌性啮齿动物的研究中,抑制CGRP信号传导主要产生镇痛作用。我们强调,很少有研究具备足够的统计效力来测量单一研究中的性别差异,并且有几项研究将不同性别的小鼠合并在一起。鉴于人类疾病中已知的性别差异,这种合并方法可能并非涉及CGRP的啮齿动物未来研究的最佳实践。总体而言,虽然有临床证据表明靶向CGRP的疗法在人类中可能具有不同的性别效应,但仍需要开展更多临床前研究来了解CGRP或CGRP拮抗在偏头痛样行为中的性别差异。